Compare Abbott Laboratories (ABT) vs Global X Cybersecurity (BUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Global X Cybersecurity — how do they compare? Abbott Laboratories trades at $95.83 (market cap $166.94B), while Global X Cybersecurity trades at $39.46. The key difference: Abbott Laboratories pays a 2.63% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | BUG | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $40.67 |
52-Week Low | $82.57 | $23.30 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BUG trades at $40.67, up 3.41% today, with a bullish technical trend supported by moving averages but overbought RSI levels. The cybersecurity ETF benefits from sector tailwinds as global spending exceeds $300 billion in 2026 (24/7 Wall Street, 2026-07-03), though AI disruption poses challenges. Key support lies at $39, with resistance at $41.
Outlook is mixed: strong sector growth supports upside, but premium valuations and AI-driven competitive threats present risks. Investors should weigh robust cybersecurity demand against potential earnings compression from rapid technological shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →
